Pharmacology & ToxicologybioRxivPreprint
Reappraisal of GPR40/FFAR1 as a Therapeutic Target for Type 2 Diabetes Mellitus: Systematic Cheminformatic Analysis of 2,637 Compounds in ChEMBL 36 Identifies Superior Candidates to Fasiglifam
This paper identifies superior GPR40 agonists to Fasiglifam using cheminformatic analysis of ChEMBL compounds, showing they have better potency, drug-likeness, and lower hepatotoxicity risk.
DOI 10.64898/2026.05.19.726272